In situ tumour arrays reveal early environmental control of cancer immunity.

ABSTRACT: The immune phenotype of a tumour is a key predictor of its response to immunotherapy^1-4. Patients who respond to checkpoint blockade generally present with immune-inflamed^5-7 tumours that are highly infiltrated by T cells. However, not all inflamed tumours respond to therapy, and even lower response rates occur among tumours that lack T cells (immune desert) or that spatially exclude T cells to the periphery of the tumour lesion (immune excluded)⁸. Despite the importance of these tumour immune phenotypes in patients, little is known about their development, heterogeneity or dynamics owing to the technical difficulty of tracking these features in situ. Here we introduce skin tumour array by microporation (STAMP)-a preclinical approach that combines high-thro

SUBMITTER: Ortiz-Munoz G 

PROVIDER: S-EPMC10284705 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature